# Centrally Acting Agents

## Examples

- `clonidine`
- `methyldopa`
  (Other related drugs: `guanfacine`, `guanabenz` — rarely used now)

> They reduce BP without postural hypotension, but cause **sedation, dry mouth, and rebound hypertension** if stopped abruptly.

## Mechanism of Action (MOA)

- These drugs **stimulate α₂-adrenergic receptors in the brainstem (medulla oblongata)**.
- → ↓ sympathetic outflow from the CNS (↓ NE release to heart, vessels, kidneys).
- → ↓ heart rate, ↓ cardiac output, ↓ peripheral vascular resistance.
- **Result:** fall in BP (mainly by reducing TPR and CO).
- `methyldopa` is a **prodrug**, converted in CNS to **α-methyl-norepinephrine**, which acts as a **false neurotransmitter** and stimulates central α₂ receptors.
- `clonidine` acts **directly** as an α₂ agonist.

![Centrally acting agents](/pharmacology/cvs/anti-hypertensives/sympatholytics/centrally-acting-agents.png)

<details>
<summary>Sympathethics vs Parasympathethics</summary>

> Sympathetic → _Fight, Flight, Fright_<br/>
> Parasympathetic → _Rest, Digest, Repair_

| Feature                               | Sympathetic Nervous System (SNS)                                     | Parasympathetic Nervous System (PNS)                         |
| ------------------------------------- | -------------------------------------------------------------------- | ------------------------------------------------------------ |
| **Origin**                            | Thoracolumbar outflow (T1–L2)                                        | Craniosacral outflow (Cranial nerves III, VII, IX, X; S2–S4) |
| **Type of Response**                  | "Fight or Flight"                                                    | "Rest and Digest"                                            |
| **Preganglionic Fiber**               | Short                                                                | Long                                                         |
| **Postganglionic Fiber**              | Long                                                                 | Short                                                        |
| **Neurotransmitter (Preganglionic)**  | Acetylcholine (ACh)                                                  | Acetylcholine (ACh)                                          |
| **Neurotransmitter (Postganglionic)** | Noradrenaline (Norepinephrine) (mostly)                              | Acetylcholine (ACh)                                          |
| **Receptors (Effector Organ)**        | Adrenergic (α, β)                                                    | Muscarinic cholinergic                                       |
| **Location of Ganglia**               | Near spinal cord (paravertebral or prevertebral ganglia)             | Near or in the effector organ                                |
| **Effect on Heart**                   | ↑ Heart rate, ↑ Contractility                                        | ↓ Heart rate, ↓ Contractility                                |
| **Effect on Bronchi**                 | Bronchodilation                                                      | Bronchoconstriction                                          |
| **Effect on Pupils**                  | Dilation (Mydriasis)                                                 | Constriction (Miosis)                                        |
| **Effect on GIT**                     | ↓ Motility, ↓ Secretions                                             | ↑ Motility, ↑ Secretions                                     |
| **Effect on Urinary Bladder**         | Relaxation of detrusor, contraction of sphincter (urinary retention) | Contraction of detrusor, relaxation of sphincter (urination) |
| **Effect on Blood Vessels**           | Mostly vasoconstriction (↑ BP)                                       | Little or no effect (except penile vasodilation)             |
| **Effect on Sweat Glands**            | Stimulated (cholinergic fibers)                                      | No effect                                                    |
| **Effect on Adrenal Medulla**         | Secretes adrenaline and noradrenaline                                | No effect                                                    |
| **Effect on Liver**                   | ↑ Glycogenolysis, ↑ Gluconeogenesis                                  | ↑ Glycogen synthesis                                         |
| **Effect on Eye (Ciliary Muscle)**    | Relaxation → far vision                                              | Contraction → near vision                                    |
| **Effect on Genital Organs**          | Ejaculation ("shoot")                                                | Erection ("point")                                           |
| **Overall Function**                  | Energy mobilization, stress response                                 | Energy conservation, body maintenance                        |

</details>

## Pharmacodynamics (Effects)

| System                  | Effect                                                           |
| :---------------------- | :--------------------------------------------------------------- |
| **Heart**               | ↓ HR, ↓ CO (negative chronotropic & inotropic).                  |
| **Vessels**             | Vasodilatation (↓ TPR).                                          |
| **Kidney**              | ↓ Renin secretion.                                               |
| **CNS**                 | Sedation, drowsiness, mental depression (CNS depressant effect). |
| **Baroreceptor reflex** | Intact — no postural hypotension (unlike ganglion blockers).     |

## Pharmacokinetics

| Property             | `Clonidine`                              | `Methyldopa`                                        |
| :------------------- | :--------------------------------------- | :-------------------------------------------------- |
| **Route**            | Oral, transdermal patch, IV              | Oral, IV                                            |
| **Absorption**       | Good oral absorption                     | Incomplete (1/3 absorbed)                           |
| **Onset / Duration** | Fast onset; lasts 6–12 h (patch: 7 days) | Slow onset; lasts 12–24 h                           |
| **Metabolism**       | Hepatic (partial)                        | Converted in CNS to α-methylnorepinephrine (active) |
| **Excretion**        | Renal                                    | Renal (mainly as sulfate conjugates)                |

## Indications

- **`Clonidine`**
  - Moderate **hypertension** (esp. resistant or in renal disease).
  - **Hypertensive crisis** (IV use).
  - **Withdrawal syndromes** — opioids, alcohol, smoking (↓ sympathetic overactivity).
  - **ADHD** (as adjunct).
  - **Menopausal hot flushes**.

- **`Methyldopa`**
  - **Hypertension in pregnancy** — _drug of choice_ (safe for mother & fetus).
  - Also used in chronic hypertension when other agents unsuitable.

## Adverse Effects

| System                       | Effect / Mechanism                                                                                              |
| :--------------------------- | :-------------------------------------------------------------------------------------------------------------- |
| **CNS**                      | Sedation, drowsiness, fatigue, mental depression (common).                                                      |
| **Cardiovascular**           | Bradycardia, hypotension, **rebound hypertension** on sudden withdrawal (esp. `clonidine`).                     |
| **GIT**                      | Dry mouth, constipation.                                                                                        |
| **Metabolic**                | Weight gain, fluid retention (mild).                                                                            |
| **Hematologic (methyldopa)** | Positive Coombs test (autoimmune hemolytic anemia), hepatitis, fever, lupus-like syndrome (rare but important). |
| **Other (clonidine)**        | Sexual dysfunction, sleep disturbances.                                                                         |

## Cautions

- Avoid abrupt withdrawal of `clonidine` → **rebound hypertension** (due to receptor upregulation).
- Use with care in **depression** (CNS suppression).
- Monitor **LFTs** and **Coombs test** periodically with `methyldopa`.
- Add **diuretic** if fluid retention occurs.

## Contraindications

- **Active depression** (for both).
- **Liver disease** (`methyldopa`).
- **History of hemolytic anemia** (`methyldopa`).
- **Bradycardia or AV block** (`clonidine`).

## Key Differences Between `Clonidine` and `Methyldopa`

| Feature              | `Clonidine`                                     | `Methyldopa`                                  |
| :------------------- | :---------------------------------------------- | :-------------------------------------------- |
| Chemical type        | Imidazoline derivative                          | α-methyl analog of DOPA                       |
| Mechanism            | Direct α₂ agonist                               | Converted to α-methyl-NE (central α₂ agonist) |
| Onset / Duration     | Rapid / short                                   | Slow / long                                   |
| Sedation             | Common                                          | Common                                        |
| Rebound hypertension | Prominent                                       | Absent                                        |
| Special use          | Withdrawal syndromes, ADHD, menopausal flushing | **Pregnancy hypertension (DOC)**              |
| Major toxicity       | Rebound HTN                                     | Hemolytic anemia, hepatitis                   |
